| Katherine Lisoni, MD | |
|
420 W 4th St, Mishawaka, IN 46544-1948 | |
| (574) 307-7673 | |
| (574) 307-7692 |
| Full Name | Katherine Lisoni |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 21 Years |
| Location | 420 W 4th St, Mishawaka, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780601351 | NPI | - | NPPES |
| 200844990 | Medicaid | IN | |
| 000000580326 | Other | IN | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 11011690 (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Joseph Regional Medical Center | Mishawaka, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthlinc Inc | 7618929373 | 57 |
News Archive
The first set of comprehensive, evidence-based clinical guidelines for surgical treatment of thyroid disease - developed by an expert panel assembled by the American Association of Endocrine Surgeons - was published today by Annals of Surgery.
Justin E. Bekelman, M.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues conducted a study to examine whether single-fraction radiation treatment, shown to be as effective as multiple-fraction treatment with less potential for harm, has been incorporated into routine clinical practice for Medicare beneficiaries with prostate cancer and at what cost savings.
Cellectis, the French genome engineering specialist, and Harvard Apparatus, a division of Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, have announced today that they have signed a license agreement that grants Harvard Apparatus the worldwide exclusive right to manufacture and sell, for research use, the full line of electroporation-based instruments acquired by Cellectis from CytoPulse in September of 2010.
Mucormycosis is a deadly infection that strikes people with weakened immune systems when certain types of fungi, called Mucorales, invade the patients' cells. A novel protein on the surface of the Mucorales cells, called CotH, makes this invasion possible.
Researchers at The Scripps Research Institute discovered that an antibody that binds and neutralizes HIV likely also targets the body's own "self" proteins. This finding could complicate the development of HIV vaccines designed to elicit this protective antibody, called 4E10, and others like it, as doing so might be dangerous or inefficient.
› Verified 2 days ago
| Entity Name | Healthlinc Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528262581 PECOS PAC ID: 7618929373 Enrollment ID: O20050210000929 |
News Archive
The first set of comprehensive, evidence-based clinical guidelines for surgical treatment of thyroid disease - developed by an expert panel assembled by the American Association of Endocrine Surgeons - was published today by Annals of Surgery.
Justin E. Bekelman, M.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues conducted a study to examine whether single-fraction radiation treatment, shown to be as effective as multiple-fraction treatment with less potential for harm, has been incorporated into routine clinical practice for Medicare beneficiaries with prostate cancer and at what cost savings.
Cellectis, the French genome engineering specialist, and Harvard Apparatus, a division of Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, have announced today that they have signed a license agreement that grants Harvard Apparatus the worldwide exclusive right to manufacture and sell, for research use, the full line of electroporation-based instruments acquired by Cellectis from CytoPulse in September of 2010.
Mucormycosis is a deadly infection that strikes people with weakened immune systems when certain types of fungi, called Mucorales, invade the patients' cells. A novel protein on the surface of the Mucorales cells, called CotH, makes this invasion possible.
Researchers at The Scripps Research Institute discovered that an antibody that binds and neutralizes HIV likely also targets the body's own "self" proteins. This finding could complicate the development of HIV vaccines designed to elicit this protective antibody, called 4E10, and others like it, as doing so might be dangerous or inefficient.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Katherine Lisoni, MD 2401 Valley Dr, Valparaiso, IN 46383-2520 Ph: (219) 413-5100 | Katherine Lisoni, MD 420 W 4th St, Mishawaka, IN 46544-1948 Ph: (574) 307-7673 |
News Archive
The first set of comprehensive, evidence-based clinical guidelines for surgical treatment of thyroid disease - developed by an expert panel assembled by the American Association of Endocrine Surgeons - was published today by Annals of Surgery.
Justin E. Bekelman, M.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues conducted a study to examine whether single-fraction radiation treatment, shown to be as effective as multiple-fraction treatment with less potential for harm, has been incorporated into routine clinical practice for Medicare beneficiaries with prostate cancer and at what cost savings.
Cellectis, the French genome engineering specialist, and Harvard Apparatus, a division of Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, have announced today that they have signed a license agreement that grants Harvard Apparatus the worldwide exclusive right to manufacture and sell, for research use, the full line of electroporation-based instruments acquired by Cellectis from CytoPulse in September of 2010.
Mucormycosis is a deadly infection that strikes people with weakened immune systems when certain types of fungi, called Mucorales, invade the patients' cells. A novel protein on the surface of the Mucorales cells, called CotH, makes this invasion possible.
Researchers at The Scripps Research Institute discovered that an antibody that binds and neutralizes HIV likely also targets the body's own "self" proteins. This finding could complicate the development of HIV vaccines designed to elicit this protective antibody, called 4E10, and others like it, as doing so might be dangerous or inefficient.
› Verified 2 days ago
Theodore R Neumann, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 611 E Douglas Rd Ste 406, Mishawaka, IN 46545 Phone: 574-335-6580 | |
Dr. Josephine Schimizzi, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1505 South Spring Street, Mishawaka, IN 46544 Phone: 574-255-0726 | |
Dale Dennis Deardorff, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 420 W 4th St, Suite 180, Mishawaka, IN 46544 Phone: 574-247-3456 Fax: 574-247-3455 | |
James Mccarrey, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4630 Vistula Rd, Mishawaka, IN 46544 Phone: 574-647-1900 | |
Dr. Jack S. Bartoszek, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 615 Fulmer Rd, Mishawaka, IN 46544 Phone: 574-252-3085 Fax: 574-252-5906 | |
Dr. Lawrence R Curry, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 524 E Mckinley Ave, Mishawaka, IN 46545 Phone: 574-256-2556 Fax: 574-258-4278 | |
Jennifer Anne Pennington, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4630 Vistula Rd, Mishawaka, IN 46544 Phone: 574-647-1900 Fax: 574-254-7222 |